Latent membrane protein 2A (LMP2A) of Epstein–Barr virus (EBV) shares protein motifs with the B-cell receptor that play a role in B-cell receptor signalling and has been shown to mimic an activated B-cell receptor by providing a survival signal for mature B cells in transgenic mice. Conversely, LMP2A has been reported not to support but to inhibit B-cell receptor signalling with respect to virus reactivation and to block lytic virus induction after anti-Ig treatment of EBV-infected B cells. To solve this apparent paradox, the role of LMP2A in lytic-cycle induction was re-examined in B cells conditionally immortalized by EBV. It was shown that, in the absence of other stimuli, LMP2A expression alone could lead to induction of the virus lytic cycle. Similarly to B-cell receptor stimulation by anti-Ig treatment, this LMP2A-mediated reactivation was dependent on the mitogen-activated protein kinase pathway and could be inhibited by the viral LMP1. Our data reinforce the notion that LMP2A is a functional homologue of the B-cell receptor, not only with respect to B-cell survival but also with respect to regulation of the lytic cycle.
AdlerB.,
SchaadtE.,
KempkesB.,
Zimber-StroblU.,
BaierB.,
BornkammG. W.2002; Control of Epstein–Barr virus reactivation by activated CD40 and viral latent membrane protein 1. Proc Natl Acad Sci U S A 99:437–442[CrossRef]
AlberG.,
KimK.-M.,
WeiserP.,
RiestererC.,
CarsettiR.,
RethM.1993; Molecular mimicry of the antigen receptor signalling motif by transmembrane proteins of the Epstein–Barr virus and the bovine leukaemia virus. Curr Biol 3:333–339[CrossRef]
BabcockG. J.,
Thorley-LawsonD. A.2000; Tonsillar memory B cells, latently infected with Epstein–Barr virus, express the restricted pattern of latent genes previously found only in Epstein–Barr virus-associated tumors. Proc Natl Acad Sci U S A 97:12250–12255[CrossRef]
BabcockG. J.,
DeckerL. L.,
FreemanR. B.,
Thorley-LawsonD. A.1999; Epstein–Barr virus-infected resting memory B cells, not proliferating lymphoblasts, accumulate in the peripheral blood of immunosuppressed patients. J Exp Med 190:567–576[CrossRef]
BabcockG. J.,
HochbergD.,
Thorley-LawsonA. D.2000; The expression pattern of Epstein–Barr virus latent genes in vivo is dependent upon the differentiation stage of the infected B cell. Immunity 13:497–506[CrossRef]
BeaufilsP.,
ChoquetD.,
MamounR. Z.,
MalissenB.1993; The (YXXL/I)2 signalling motif found in the cytoplasmic segments of the bovine leukaemia virus envelope protein and Epstein–Barr virus latent membrane protein 2A can elicit early and late lymphocyte activation events. EMBO J 12:5105–5112
BrielmeierM.,
BechetJ. M.,
SuppmannS.,
ConradM.,
LauxG.,
BornkammG. W.2001; Cloning of phospholipid hydroperoxide glutathione peroxidase (PHGPx) as an anti-apoptotic and growth promoting gene of Burkitt lymphoma cells. Biofactors 14:179–190[CrossRef]
CaldwellR. G.,
WilsonJ. B.,
AndersonS. J.,
LongneckerR.1998; Epstein–Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. Immunity 9:405–411[CrossRef]
DeckerL. L.,
KlamanL. D.,
Thorley-LawsonD. A.1996; Detection of the latent form of Epstein–Barr virus DNA in the peripheral blood of healthy individuals. J Virol 70:3286–3289
DykstraM. L.,
LongneckerR.,
PierceS. K.2001; Epstein–Barr virus coopts lipid rafts to block the signaling and antigen transport functions of the BCR. Immunity 14:57–67[CrossRef]
FentonM.,
SinclairA. J.1999; Divergent requirements for the MAPKERK signal transduction pathway during initial virus infection of quiescent primary B cells and disruption of Epstein–Barr virus latency by phorbol esters. J Virol 73:8913–8916
FruehlingS.,
LeeS.,
HerroldR.,
FrechB.,
LauxG.,
KremmerE.,
GrässerF. A.,
LongneckerR.1996; Identification of latent membrane protein 2A (LMP2A) domains essential for the LMP2A dominant-negative effect on B-lymphocyte surface immunoglobulin signal transduction. J Virol 70:6216–6226
HiguchiM.,
IzumiK. M.,
KieffE.2001; Epstein–Barr virus latent-infection membrane proteins are palmitoylated and raft-associated: protein 1 binds to the cytoskeleton through TNF receptor cytoplasmic factors. Proc Natl Acad Sci U S A 98:4675–4680[CrossRef]
HochbergD.,
MiddeldorpJ. M.,
CatalinaM.,
SullivanJ. L.,
LuzuriagaK.,
Thorley-LawsonD. A.2004a; Demonstration of the Burkitt's lymphoma Epstein–Barr virus phenotype in dividing latently infected memory cells in vivo. Proc Natl Acad Sci U S A 101:239–244[CrossRef]
KempkesB.,
SpitkovskyD.,
Jansen-DurrP.,
EllwartJ. W.,
KremmerE.,
DelecluseH. J.,
RottenbergerC.,
BornkammG. W.,
HammerschmidtW.1995; B-cell proliferation and induction of early G1-regulating proteins by Epstein–Barr virus mutants conditional for EBNA2. EMBO J 14:88–96
KempkesB.,
Zimber-StroblU.,
EissnerG.,
PawlitaM.,
FalkM.,
HammerschmidtW.,
BornkammG. W.1996a; Epstein–Barr virus nuclear antigen 2 (EBNA2)–oestrogen receptor fusion proteins complement the EBNA2-deficient Epstein–Barr virus strain P3HR1 in transformation of primary B cells but suppress growth of human B cell lymphoma lines. J Gen Virol 77:227–237[CrossRef]
KempkesB.,
Zimber-StroblU.,
EissnerG.,
PawlitaM.,
FalkM.,
HammerschmidtW.,
BornkammG. W.1996b; Epstein–Barr virus nuclear antigen 2 (EBNA2)-oestrogen receptor fusion proteins complement the EBNA2-deficient Epstein–Barr virus strain P3HR1 in transformation of primary B cells but suppress growth of human B cell lymphoma lines. J Gen Virol 77:227–237[CrossRef]
KieserA.,
KaiserC.,
HammerschmidtW.1999; LMP1 signal transduction differs substantially from TNF receptor 1 signaling in the molecular functions of TRADD and TRAF2. EMBO J 18:2511–2521[CrossRef]
KonishiK.,
MaruoS.,
KatoH.,
TakadaK.2001; Role of Epstein–Barr virus-encoded latent membrane protein 2A on virus-induced immortalization and virus activation. J Gen Virol 82:1451–1456
LauxG.,
FreeseU. K.,
BornkammG. W.1985; Structure and evolution of two related transcription units of Epstein–Barr virus carrying small tandem repeats. J Virol 56:987–995
LauxG.,
PerricaudetM.,
FarrellP. J.1988; A spliced Epstein–Barr virus gene expressed in immortalized lymphocytes is created by circularization of the linear viral genome. EMBO J 7:769–774
LauxG.,
EconomouA.,
FarrellP. J.1989; The terminal protein gene 2 of Epstein–Barr virus is transcribed from a bidirectional latent promoter region. J Gen Virol 70:3079–3084[CrossRef]
MillerC. L.,
LeeJ. H.,
KieffE.,
LongneckerR.1994; An integral membrane protein (LMP2) blocks reactivation of Epstein–Barr virus from latency following surface immunoglobulin crosslinking. Proc Natl Acad Sci U S A 91:772–776[CrossRef]
MiyashitaE. M.,
YangB.,
BabcockG. J.,
Thorley-LawsonD. A.1997; Identification of the site of Epstein–Barr virus persistence in vivo as a resting B cell. J Virol 71:4882–4891
PolackA.,
LauxG.,
HergenhahnM.,
KlozU.,
RoeserH.,
HeckerE.,
BornkammG. W.1992; Short-term assays for detection of conditional cancerogens. I. Construction of DR-CAT Raji cells and some of their characteristics as tester cells. Int J Cancer 50:611–616[CrossRef]
RabsonM.,
HestonL.,
MillerG.1983; Identification of a rare Epstein–Barr virus variant that enhances early antigen expression in Raji cells. Proc Natl Acad Sci U S A 80:2762–2766[CrossRef]
RickinsonA. B.,
KieffE.2001; Epstein–Barr virus. In Fields Virology , 4th edn. pp 2575–2627 Edited by
KnipeD. M.,
HowleyP. M.,
GriffinD. E.,
MartinM. A.,
LambR. A.,
RoizmanB.,
StrausS. E.
Philadelphia: Lippincott Williams & Wilkins;
SugdenB.,
MarshK.,
YatesJ.1985; A vector that replicates as a plasmid and can be efficiently selected in B-lymphoblasts transformed by Epstein–Barr virus. Mol Cell Biol 5:410–413
TierneyR. J.,
StevenN.,
YoungL. S.,
RickinsonA. B.1994; Epstein–Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state. J Virol 68:7374–7385
Zimber-StroblU.,
KempkesB.,
MarschallG.,
ZeidlerR.,
Van KootenC.,
BanchereauJ.,
BornkammG. W.,
HammerschmidtW.1996; Epstein–Barr virus latent membrane protein (LMP1) is not sufficient to maintain proliferation of B cells but both it and activated CD40 can prolong their survival. EMBO J 15:7070–7078